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Abstract
Background: Curcumin inhibits the growth of esophageal cancer cell lines; however, the mechanism of action is not well
understood. It is becoming increasingly clear that aberrant activation of Notch signaling has been associated with the
development of esophageal cancer. Here, we have determined that curcumin inhibits esophageal cancer growth via a
mechanism mediated through the Notch signaling pathway.
Methodology/Principal Findings: In this study, we show that curcumin treatment resulted in a dose and time dependent
inhibition of proliferation and colony formation in esophageal cancer cell lines. Furthermore, curcumin treatment induced
apoptosis through caspase 3 activation, confirmed by an increase in the ratio of Bax to Bcl2. Cell cycle analysis
demonstrated that curcumin treatment induced cell death and down regulated cyclin D1 levels. Curcumin treatment also
resulted in reduced number and size of esophagospheres. Furthermore, curcumin treatment led to reduced Notch-1
activation, expression of Jagged-1 and its downstream target Hes-1. This reduction in Notch-1 activation was determined to
be due to the down-regulation of critical components of the c-secretase complex proteins such as Presenilin 1 and Nicastrin.
The combination of a known c-secretase inhibitor DAPT and curcumin further decreased proliferation and induced
apoptosis in esophageal cancer cells. Finally, curcumin treatment down-regulate the expressions of Notch-1 specific
microRNAs miR-21 and miR-34a, and upregulated tumor suppressor let-7a miRNA.
Conclusion/Significance: Curcumin is a potent inhibitor of esophageal cancer growth that targets the Notch-1 activating c-
secretase complex proteins. These data suggest that Notch signaling inhibition is a novel mechanism of action for curcumin
during therapeutic intervention in esophageal cancers.
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Introduction
Esophageal cancer is the eighth most common incident cancer in
the world and sixth in cancer mortality [1]. In the United States, 4–
10 in 100,000 persons succumb to the disease per year and the
overall incidenceofthe disease ishighestinmenover50yearsofage
[2]. The American Cancer Society (ACS) estimated that in 2011,
16,980 Americans (13,450 men and 3,530 women) would be
diagnosed with esophageal cancer. The ACS also estimated that the
majority of these individuals [14, 710 Americans (11,910 men and
2,800 women)] would die of esophageal cancer in 2011 [3].
Esophageal adenocarcinoma, the major form of esophageal cancer
in the US, is the mostrapidly rising cancer in the western world. It is
generally diagnosed at a late stage and has a poor prognosis, with a
5-year survival of less than 10%. Although the current treatment
includes chemotherapy, radiation therapy, and, if possible,
esophagogastric resection, many patients with esophageal adeno-
carcinomaexperience progression ofdiseasedespite suchtreatment,
suggesting that such tumors are resistant to standard therapy.
Because conventional therapies, including surgical resection,
chemotherapy, and radiation are often inadequate in treating this
disease, new treatment options are critically needed. Despite the
emergence of novel targeted agents and the use of various
therapeutic combinations, no treatment options are available that
are curative in patients with advanced cancer. The magnitude of
this problem mandates the need for novel therapeutic agents,
specifically the use of agents for chemoprevention. This is most
attractive for esophageal adenocarcinoma since a pre-malignant
condition -Barrett’s esophagus is a well-recognized lesion.
Curcumin, a phyto-polyphenolic pigment derived from turmer-
ic (Curcuma longa), has been shown to have multiple anticancer
effects, including inhibition of proliferation, induction of apoptosis,
inhibition of angiogenesis, and inhibition of DNA topoisomerase II
[4]. Curcumin also induces apoptosis-independent death such as
autophagy in esophageal cancer cells [5]. Recent studies have
demonstrated that curcumin promotes apoptosis, increases
chemosensitivity, and inhibits NF-kB in esophageal adenocarci-
noma [6] [7].
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  (PS) dsub   ramaniam@kumc.edu  (D.  Subramaniam);Notch signaling plays a critical role in the development and
homeostasis of tissues by regulating cell-fate decisions, prolifera-
tion, differentiation, and apoptosis. Notch signaling pathway is
implicated in stem cell self-renewal, cell-fate determination,
proliferation, differentiation and apoptosis [8]. Notch signaling is
upregulated in esophageal cancers and has been proposed as a
therapeutic target for esophageal cancers [9] [10]. Notch signaling
is initiated when a notch ligand interacts with a notch
transmembrane receptor on a adjacent cells [11] [12]. This
process usually initiates the c-secretase mediated proteolytic
release of the Notch intracellular domain (NICD), which, in turn,
translocates into the nucleus of the cells [13]. The NICD in the
nucleus interacts with the C promoter-binding factor-1 (CBF1)
transcriptional cofactor and transactivates the target genes, such as
those in the hairy and enhancer of split (Hes) and Hes related with
YRPW motif (Hey) families [12] [14]. Recent studies have
demonstrated a connection between curcumin, Notch and NF-
kB. Notch-1 signaling pathway has been directly shown to be
activated by NF-kB in oral cancer cells [15]. Moreover, curcumin-
mediated inhibition of Notch-1 activation also led to the
downregulation of NF-kB and its target genes, including Bcl-2,
cyclin D1, vascular endothelial growth factor (VEGF), and matrix
metalloproteinase -9 (MMP-9) in oral squamous cell carcinoma
cells [4].
MicroRNAs (miRNAs) are short non-coding RNAs that bind to
the 39 untranslated region (UTR) of cognate messenger RNAs
(mRNAs) through fully complementary or imperfect base-pairing
repressing the translation or decreasing the stability of the bound
mRNAs [16]. Some miRNAs are reported as oncomirs which
could function as either oncogenes or tumor suppressors [17]. For
example, miR-21 decreases tumor suppressor Pdcd4 expression
and promotes invasion, intravasation and metastasis in colorectal
cancer [18]. Upregulation of miR-21 is strongly associated with
both a high Ki-67 proliferative index and the presence of liver
metastasis [19]. miR-21 also regulated PTEN-dependent pathway
and affected cell growth, migration and invasion of hepatocellular
carcinoma[20]. Recently, we have demonstrated miRNAs as
biomarkers for Barrett’s esophagus progression. miR-21 is
upregulated 12.57-fold in esophageal cancer [21]. Another
important miRNA is miR-34, which has been found to participate
in the regulation of p53 and Notch pathways consistent with tumor
suppressor activity [22]. A recent study demonstrated that there is
a cross-talk between miRNA and Notch signaling pathways in
tumor development and progression [23]. Moreover, Notch
signaling and its regulations are critically important at the level
of post-transcriptional and/or translational regulation of genes by
miRNAs in glioblastoma [24]. On the other hand, let-7a decreases
cell proliferation and migration of glioblastoma and reduces tumor
size in xenograft model [25].
In this article, we have determined the effect of curcumin on




TE-7, TE-10 are human and ESO-1 is mouse esophageal
adenocarcinoma cancer cells that were kindly provided by Dr.
Richard J. Battafarano, University of Maryland and grown in
RPMI 1640 containing 10% heat inactivated fetal bovine serum
(Sigma-Aldrich, St. Louis, MO) and 1% antibiotic-anti-mycotic
solution (Mediatech Inc, Manassas, VA) at 37uC in a humidified
atmosphere of 5% CO2. Curcumin was purchased from LKT
Laboratories, St. Paul, MN. N-[N-(3,5-Difluorophenacetyl)-L-
alanyl]-S-phenylglycine t-butyl ester (DAPT) was purchased
(Sigma-Aldrich, St. Louis, MO).
Proliferation and Apoptosis assays
To assess proliferation, cells were seeded on to 96 well plates
and grow overnight. Then the cells were treated with increasing
doses of curcumin in 10% FBS containing RPMI 1640. Analysis of
cell proliferation was performed by enzymatic assay as described
[26]. For apoptosis, caspase 3/7 activity was measured using the
Apo-one Homogeneous Caspase-3/7 Assay kit (Promega, Madi-
son, WI).
Colony formation assay
Briefly, 6 well dishes were seeded with 500 viable cells and
allowed to grow for 24 h. The cells were then incubated in the
presence or absence of 30 mM curcumin for 24 h. Curcumin
containing medium was then removed, and the cells were washed
in PBS and incubated for an additional 10 d in complete medium.
Each treatment was done in triplicate. The colonies obtained were
washed with PBS and fixed in 10% formalin for 10 min at room
temperature and then washed with PBS followed by staining with
Crystal violet. The colonies were counted and compared with
untreated cells.
Cell cycle analyses
Cells were treated with 30 mM of curcumin for 12 and 24 h,
then cells were trypsinized and suspended in phosphate buffered
saline (PBS). Single-cell suspensions were fixed using 70% ethanol
for 2 h, and subsequently permeabilized with PBS containing
1 mg/ml propidium iodide (Sigma-Aldrich), 0.1% Triton X-100
(Sigma-Aldrich) and 2 mg DNase-free RNase (Sigma-Aldrich) at
room temperature. Flow cytometry was done with a FACSCalibur
analyzer (Becton Dickinson, Mountain, View, CA), capturing
10,000 events for each sample. Results were analyzed with ModFit
LT
TM software (Verity Software House, Topsham, ME).
Real Time Reverse-Transcription Polymerase Chain
Reaction Analysis
Total RNA isolated from TE-7 cells using TRIZOL reagent was
reverse transcribed with Superscript II reverse transcriptase in the
presence of random hexanucleotide primers (all from Invitrogen,
Carlsbad, CA).Complementary DNAs werethen used for Real Time
PCR using Jumpstart Taq DNA polymerase (Sigma-Aldrich) and
SYBR Green nucleic acid stain (Molecular Probes, Eugene, OR).
Crossing threshold values for individual genes were normalized to b-
Actin. Changes in mRNA expression were expressed as fold change
relativeto control. Primers used in this study wereas follows: b-Actin:
59-GCTGATCCACATCTGCTGG-39 and 59-ATCATTCTCCT-
CCTCAGCG-39; Cyclin D1: 59-AATGACCCCGCACGATTT-
C-39 and 59-TCAGGTTCAGGCCTTGCAC-39;N o t c h - 1 :5 9-CA-
CTGTGGGCGGGTCC-39 and 59-GTTGTATTGGTTCGGC-
ACCAT-39;H e s - 15 9-AGGCGGACATTCTGGAAATG-39 and
59-CGGTACTTCCCCAGCACACTT-39; Presenilin-1 59 ATC-
ATGCTCTTTGTCC-39 and 59- TCTTCTGTGAATGGG-39;
Nicastrin 59-CAGATTGGCTGCCAGT-39 and 59-CTCCAGCA-
GAACCAT-39.
miRNA analysis
Total miRNA was isolated using mirVana
TM miRNA isolation
kit (Ambion Inc, Grand Island, NY). Total miRNA isolated from
TE-7 cells were subjected to reverse transcription with Super-
script
TM II RNase H-Reverse Transcriptase and random
hexanucleotide primers (Invitrogen). The cDNA was subsequently
Curcumin Inhibits Notch in Esophageal Cancer
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Green I; Molecular Probes) for pri-let-7a transcript using specific
primers and Jumpstart Taq DNA polymerase (Sigma-Aldrich, St.
Louis, MO). The crossing threshold value assessed by Real time
PCR was noted for pri-let-7a miRNA and normalized with U6 pri-
miRNA. The changes in pri-miRNA were expressed as fold
change relative to control with 6 SEM value. Primers used are:
pri-U6:5 9-CTCGCTTCGGCAGCACA-39 and 59-AACGCTT-
CACGAATTTGCGT-39, pri-let-7a:5 9-GAGGTAGTAGGTTG-
TATAGTTTAGAA-39,5 9-AAAGCTAGGAGGCTGTACA-39.





Cell lysates were subjected to polyacrylamide gel electrophoresis
and blotted onto Immobilon-P polyvinylidene difluoride mem-
branes (Millipore, Bedford, MA). Notch-1, Caspase 3, Bcl2 and
Bax antibodies were purchased from Cell Signaling Technology
(Beverly, MA). Cyclin D1, Notch-1, Jagged-1, Hes-1 and Actin
antibodies were purchased from Santa Cruz Biotechnology Inc
(Santa Cruz, CA). Presenilin 1, 2, Nicastrin, APH1 and Pen2
antibodies from GenScript Inc (Piscataway, NJ) and specific
proteins were detected by the enhanced chemiluminescence
system (GE Healthcare, Piscataway, NJ).
Spheroid assay
For formation of spheroids, cells were cultured in RPMI 1640
(Mediatech) supplemented with 20 ng/ml bFGF (Invitrogen) 10 mL
per 500 mL of 50X B27 supplement (Invitrogen) EGF 20 ng/ml
(Invitrogen) and antibiotic and antimycotic solution. Cells were
seeded at low densities (5000 cells/mL) in 6 well low adhesion plates.
The cells were treated with increasing concentrations of curcumin
(0–50 mM). After 7 days the spheroids were photographed.
Immunofluorescence staining
The cells were plated over night on cover-slips on six well plates.
After treatment with 30 mM of curcumin for 24 h, cells were then
fixed with paraformaldehyde for 15 min, rinsed with PBS, and
incubated with 2% bovine serum albumin in PBS for 30 min. The
cells were then incubated overnight with anti-Notch-1, anti-
Jagged-1, anti-Hes-1, anti-Presenilin 1 and anti-Nicastrin anti-
body, respectively. After washing with PBS, the cells were
incubated with Cy-3-conjugated secondary antibody for 30 min
and washed with PBS. Cell images were observed under a
fluorescent microscope.
Statistical analysis
All values are expressed as the mean 6 SEM. Data was
analyzed using an unpaired 2-tailed t test. P value of less than 0.05
was considered statistically significant.
Results
Curcumin inhibits esophageal cancer cell growth
We determined the effect of curcumin on esophageal cancer cell
proliferation in a variety of cultured cell lines (TE-7, TE-10 and
Eso-1). Curcumin significantly suppressed the proliferation of
esophageal cancer cell lines TE-7, TE-10 and Eso-1 in dose and
time dependent manner. This anti-proliferation effect on tumor
cells was seen within a 24 h period, which continued to
significantly increase over the next 72 h (Figure 1A). To determine
the long-term effect of curcumin treatment, cells were treated with
30 mM curcumin for 24 h, following which the cells were allowed
to grow in normal media. Curcumin treatment suppressed colony
formation in all esophageal cancer cell lines (Figure 1B), suggesting
that curcumin’s effect on the tumor cells was irreversible. Cyclin
D1 is one the cell cycle regulatory protein that regulates the G1 to
S-phase transition of the cell cycle and functions as a cofactor for
several transcription factors in numerous cell lines. This cyclin
forms a complex with and functions as regulatory subunit of
CDK4 or CDK6, whose activity is required for G1/S transition.
Cyclin D1 overexpression has been linked to the development and
progression of cancer [27]. Curcumin treatment inhibited cyclin
D1 mRNA and protein expression suggesting that it inhibits
cancer cell proliferation. On the other hand, expression of p21
protein was increased (Figure 1C and D).
Curcumin induces cell death by apoptosis
Given the effects of curcumin on suppression of proliferation
and colony formation, we next determined whether curcumin
affects cell cycle progression. Treatment with curcumin signifi-
cantly induced cell death of TE-7 cells within 12 h and
continuously increased up to 24 h (Figure 2A). Such similar
increases in cell death have been observed in other cell types [28].
Curcumin is known to induce apoptosis in variety of cancer cells.
The caspases are a family of proteins known for the execution of
apoptosis. Caspase-3 and caspase-7 are key effector molecules
known to induce apoptosis in variety of cancer cells by amplifying
the signal from initiator caspases, such as caspase-8 or caspase-10.
Increased activation of effector caspase-3 and caspase-7 was
observed within 24 hours in the TE-7 cell line treated with
curcumin suggesting induction of apoptosis (Figure 2B). Western
blot analyses of TE-7 cell lysates demonstrated a significant
decrease in procaspase-3 in curcumin treated tumor cells
(Figure 2C). Further confirmation that the cells were undergoing
apoptosis was obtained by western blot analyses for anti-apoptotic
Bcl2 and BclxL and pro-apoptotic Bax proteins. Curcumin
treatment inhibited the expression of Bcl2 and BclxL and
increased Bax protein levels. These data suggest that curcumin
is a potent inducer of apoptosis in esophageal cancer cells
(Figure 2D).
Curcumin inhibits esophagosphere formation
Given that curcumin inhibits colonosphere formation in colon
cancer cells and affecting Notch signaling pathway proteins. We
next determined the effects of curcumin on esophageal cancer cell
spheroid formation. Curcumin treatment significantly inhibited
esophagosphere formation in a dose dependent manner in both
TE-7 and TE-10 cells (Figure 3A). The spheroids size, numbers
were counted. Curcumin treatment reduced both primary and
secondary spheroid formation (Figure 3B and C).
Curcumin inhibits Notch activation by downregulating
the c-secretase complex
Notch-1 is a cell membrane associated protein. Ligand
engagement causes the intracellular domain of the transmembrane
receptor Notch (NICD) to be cleaved from the membrane through
the action of the c-secretase complex. NICD translocates to the
nucleus, where it associates with a family of DNA binding proteins
to activate transcription of Notch target genes such as hairy and
enhancer-of-split 1 (Hes1) [29]. We determined the effect of
curcumin on Notch-1, its ligand Jagged-1 and Hes-1 in TE-7 cells.
Curcumin treatment significantly downregulated Notch-1 and its
ligand Jagged-1 and downstream target proteins Hes-1 both
mRNA and protein levels (Figure 4A and B). Protein levels were
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lower levels of nuclear Notch-1 and cytoplasmic Jagged-1 were
observed in the curcumin treated cells (Figure 4C).
We next determined the mechanism by which curcumin affects
Notch-1 activation. c-secretase is a multi-protein complex
containing an intra-membrane cleaving protease. The complex
has a growing list of proteins substrates, including the Notch
receptors. The four components of c-secretase complex, Presenilin
1, Nicastrin, Pen2, and Aph1 are all thought to be essential for
activity [13] [30] [31]. The catalytic domain resides within
Presenilin, while Nicastrin has been suggested to be critical for
substrate recognition [32]. Curcumin treatment resulted in down-
regulation in the expression of c-secretase complex proteins,
Presenilin 1 and 2, Nicastrin, APH1 and PEN2 (Figure 5A, B and
C). These data suggest that curcumin mediated down-regulation of
the Notch signaling pathway occurs in part through the inhibition
of the c-secretase complex.
Combination of curcumin and a c-secretase complex
inhibitor DAPT further affects esophageal cancer growth
Treatment with combination of curcumin and a c-secretase
complex inhibitor (GSI) DAPT further inhibits Notch-1 target
Figure 1. Curcumin inhibits esophageal cancer cell proliferation. (A) Curcumin inhibits proliferation of esophageal cancer cells. Cells were
incubated with increasing doses of curcumin (0–50 mM) for up to 72 h and analyzed for cell proliferation. Curcumin treatment resulted in a significant
dose- and time-dependent decrease in cell proliferation in all three cells when compared with untreated controls. (B) Curcumin inhibits colony
formation. Esophageal cancer cells were incubated with 30 mM of curcumin for 24 h and allowed to grow into colonies for 10 days. Incubation with
curcumin inhibits colony formation. Results are representative of three independent experiments. (C) Cyclin D1 is one the cell cycle regulatory protein
and which is involved in the cell cycle arrest. RNA from TE-7 incubated with 30 mM curcumin was subjected to Real Time PCR for cyclin D1 mRNA
expression. Curcumin treatment significantly inhibits cyclin D1 mRNA expression (*p,0.05). (D) Lysates from TE-7 incubated with 30 mM curcumin
were analyzed by western blotting for cyclin D1 expression levels using mouse anti-cyclin D1 antibody. Curcumin treatment inhibits cyclin D1 protein
expression.
doi:10.1371/journal.pone.0030590.g001
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performed combination of curcumin with a c-secretase complex
inhibitor DAPT on proliferation and apoptosis. Combination of
curcumin and DAPT treatment further inhibits proliferation and
induces apoptosis in TE-7 cells (Figure 6B and C). Similar results
were observed in TE-10 cells (data not shown).
Curcumin inhibits oncomir miRNA and increases tumor
suppressor miRNA in esophageal cancer cells
Curcumin alters microRNA expression in colon [33] pancreas
[34], breast [35], bladder [36] and lung [37] cancer cells.
Recently, we have demonstrated that miRNAs as biomarkers for
Barrett’s esophagus progression and miR-21 is upregulated 12.57
Figure 3. Curcumin treatment inhibits esophageal cancer cells spheroid formation. (A) TE-7 and TE cells were grown in low adherent
plates and treated with increasing concentrations of curcumin (0–50 mM) and performed for the spheroid assay. After one week, the spheroids were
photographed. (B) Spheroid was counted and performed bar diagram. Curcumin treatment significantly inhibited esophageal cancer cells spheroids
(*p,0.05). (C) The primary spheroids were collected and separated into single cells and replated. Curcumin treatment significantly inhibited
esophageal cancer cells secondary spheroids (*p,0.05).
doi:10.1371/journal.pone.0030590.g003
Figure 2. Curcumin induces cell death and apoptosis. (A) Cell cycle analysis of curcumin treated cells. TE-7 cells were treated with 30 mMo f
curcumin for 12 and 24 h, examined by flow cytometry following propidium iodide staining for DNA content. Curcumin treatment leads to increased
number of dead cells. Graphs are representative of data collected from three experiments. (B) Curcumin induces caspase-3, an apoptosis mediator.
TE-7 cells incubated with 30 mM of curcumin were analyzed for apoptosis by caspase-3 and-7 activation. Curcumin treatment increased the number
of cells undergoing apoptosis compared to untreated controls (*p,0.05). (C) Lysates from TE-7 cells incubated with 30 mM of curcumin were
analyzed by western blotting for caspase-3 protein levels using rabbit anti-caspase-3 antibody. Curcumin treatment resulted in decreased
procaspase-3. (D) Lysates from TE-7 cells incubated with 30 mM of curcumin were analyzed by western blotting for Bcl2, BclxL, and Bax proteins.
Curcumin reduces expression of anti-apoptotic proteins Bcl2 and BclxL, whereas increased expression of pro-apoptotic proteins in treated cells when
compared to untreated cells.
doi:10.1371/journal.pone.0030590.g002
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curcumin on oncomir miRNA and tumor suppressor miRNA
esophageal cancer cells. Curcumin treatment significantly down
regulated miR-21 and miR-34a expression while upregulating let-
7a miRNA expression (Figure 7A and B).
Discussion
Esophageal cancer is one of the sixth leading causes of cancer-
related deaths in the western world. Overall incidence of the
disease is highest in men over 50 years of age [2]. Esophageal
cancer is generally diagnosed at a late stage and has a poor
prognosis, with a 5-year survival of less than 10%. The significant
morbidity, toxicity and poor response rates of current chemother-
apy regimens have led to searches for less toxic alternative
therapies. We and others have shown that curcumin suppresses
proliferation and induces apoptosis in a variety of tumor cells,
including pancreas, breast, colon, oral, lung, melanoma, myeloma,
leukemia, and prostate carcinoma. Previous studies have shown
that curcumin suppresses the proliferation and increases apoptosis
in esophageal cancer cells [5] [6] [38] [39].
The data presented in this article show that curcumin selectively
inhibits the proliferation of esophageal cancer cells, suppresses the
formation of esophageal cancer cell colonies, promotes cell cycle
arrest and apoptosis, inhibits esophagosphere formation, down
regulates notch signaling and its c-secretase complex proteins, and
also inhibits oncomir miRNA expression and induces tumor
suppressor miRNA expression. These results are further presented
in the schematic diagram in Figure 8. Our results show that
curcumin can effectively suppress cell proliferation within 24 h.
Moreover, the inhibitory effects on tumor cells appear to be
sustained and irreversible after 24 h of treatment. Our data with
cyclin D1 is intriguing in that there was a reduction in its
expression at 24 h. This should have resulted in cells undergoing
G0-G1 arrest since the protein is responsible for progression
through the G0–G1/S phase transition [40]. Similar curcumin-
Figure 4. Curcumin inhibits notch signaling and its downstream targets proteins. (A) real-time reverse transcription-PCR analysis of total
RNA from TE-7 cells following 30 mM of curcumin treatment for 24 h showed reduction in the expression of Notch-1, its ligand Jagged-1 and its target
gene Hes-1 mRNA (*p,0.05). (B) lysates from curcumin treatment caused significant reduction in the expression of cleaved Notch-1, its ligand
Jagged-1and its target gene Hes-1 protein levels in TE-7 cells. (C) TE-7 cells treated with 30 mM of curcumin for 24 h were subjected to immuno-
fluorescent staining using anti-Notch-1, anti-Jagged-1 and anti-Hes-1 antibodies. Curcumin treatment resulted in lower levels of Notch-1 proteini n
the nucleus and reduced Jagged-1 and Hes-1 expression in TE-7 cells.
doi:10.1371/journal.pone.0030590.g004
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cancer cell types, including colon and gastric cancers, and in
mantle cell lymphoma [28] [41]. Indeed, we observed a significant
increase in dead cells in the esophageal cancer cells even at 12 h
following incubation with curcumin, which subsequently led to cell
death.
In the present study, we also found that curcumin down
regulates Notch signaling through the inhibition of the c-secretase
complex. Curcumin inhibits Notch-1 and its ligand Jagged-1 in
esophageal cancer cells. We also found that curcumin inhibited the
expression of the Notch-1 downstream target Hes-1. Recently, it
has been reported that the Notch pathway plays critical roles in
the processes of tumor cell proliferation, apoptosis and stem cell
maintenance and is closely associated with tumorigenesis in
esophageal cancer cells [42]. Therefore, curcumin mediated cell
growth inhibition could be partly mediated via inactivation of
Notch-1 activity. This was further confirmed by the combination
of a GSI and curcumin, which further inhibited proliferation and
induced apoptosis. Similarly, the combination of curcumin with a
GSI further inhibited Hes-1 and cyclin D1 expressions. However,
Notch-1 is not the only pathway active in esophageal cancer as
many other cellular pathways are activated [7] [39]. It would be
interesting to determine whether curcumin is equally potent in
inhibiting other signal transduction pathways. In addition, it would
be interesting to determine whether ectopic expression of Notch
downstream target genes such as Hes-1 and c-myc in the condition
of Notch knockdown or rescue protects from curcumin-mediated
cell death.
Notch signaling is required for stem cell self-renewal and
maintaining the stemness [43]. One method that is commonly
used to demonstrate stemness is the growth of spheroids in ultra-
Figure 5. Curcumin inhibits c-secretase complex proteins. (A)
real-time reverse transcription-PCR analysis of total RNA from TE-7 cells
following 30 mM of curcumin treatment for 24 h showed reduction in
the expression of Presenilin 1 and Nicastrin mRNA (*p,0.05). (B) lysates
from curcumin treatment caused significant reduction in the expression
of c-secretase complex proteins Presenilin 1 and 2, Nicastrin, APH1 and
Pen2 protein levels in TE-7 cells. (C) TE-7 cells treated with 30 mMo f
curcumin for 24 h were subjected to immuno-fluorescent staining
using anti-Presenilin 1 and anti-Nicastrin antibodies. Curcumin treat-
ment resulted in lower levels of Presenilin 1 and Nicastrin expression in
TE-7cells.
doi:10.1371/journal.pone.0030590.g005
Figure 6. Combination of Curcumin and DAPT further inhibit
proliferation and induce apoptosis. (A) TE cells treated with DAPT
(50 mM) and curcumin (30 mM) alone and in combination for 24 h.
Lysates were analyzed by western blotting. Hes-1 and Cyclin D1
proteins were further decreased with the combination of the two
compounds. (B) TE cells treated with DAPT (50 mM) and curcumin
(30 mM) alone and in combination for 48 h. Cell proliferation was
significantly inhibited following treatment with the combination of
DAPT and curcumin when compared to each curcumin alone using
hexosaminidase enzyme assay (*P,0.05). (C) Apoptosis was significant-
ly induced following treatment with the combination of DAPT and
curcumin when compared to each curcumin alone using Apo-one
Homogeneous Caspase-3/7 Assay kit (*P,0.05).
doi:10.1371/journal.pone.0030590.g006
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early stemness preservation. For esophageal-derived cells, these
spheroids are called esophagospheres. Curcumin is a potent
inhibitor of esophagosphere formation suggesting that it targets
Notch signaling to affect cancer stem cells.
MicroRNAs can normalize multiple coding genes associated
with tumor growth, and thus, assessment of specific miRNA
expression could be useful for predicting disease outcome. It is well
known that the development of cancer involves alterations in the
expression of multiple genes regulated by transcriptional, post-
transcription, translational, and posttranslational modification,
and thus, a single gene or protein expression cannot accurately
reflect the status of the disease. We have recently demonstrated
that miRNAs [18] as biomarkers for Barrett’s esophagus
progression [21]. Several miRNAs upregulated significantly and
specifically miR-21 is up-regulated 12.57 fold in esophageal cancer
[21]. miR-21 is overexpressed in many solid tumors and has been
shown to be associated with tumor progression, poor survival, and
reduced therapeutic effects [44]. Curcumin treatment significantly
reduced miR-21 expression in colon and pancreatic cancers,
thereby inhibiting invasion and metastasis in colon cancer [33]
[45]. Our result in esophageal cancer cells correlates with these
previous findings. Several targets have been identified for miR-21.
The microRNA has been shown to downregulate expression of
tumor suppressor gene Pdcd4 in colorectal cancer cells, thereby
stimulating tumor invasion, intravasation and metastasis [18].
miR-21 can also inhibit apoptosis in breast cancer cells by
regulating Bcl2 expression [46]. Finally, miR-21 can inhibit
gemcitabine-induced apoptosis via the PTEN and PI-3 kinase
pathway [20]. It would be interesting to determine whether
curcumin affects the expression of these genes in the esophageal
cancer cells, and whether this expression can be modulated by
miR-21.
In our current study we did not observe increased miR-34a
expression in response to curcumin, which was surprising because
miR-34a is a tumor suppressor microRNA and upregulation of
this microRNA induces cells to undergo apoptosis. However,
previous studies have demonstrated that the altered expression of
miR-34a in esophageal cancer tissue specimens did not show a
significant association with the patients’ clinico-pathologic param-
eters and survival [47]. Also, tumor suppressor protein p53 is
known to induce miR-34a expression thereby leading cells to
apoptosis. However, esophageal cancer cells (and cell lines) are
either p53 deficient (TE-7) or have mutations leading to
accumulation of mutant, non-functional p53 protein (TE-10)
[48]. This could be a reason why miR-34a is not upregulated in
response to curcumin treatment. One other reason for the lack of
miR-34a upregulation could be that previous studies have shown
that in cells where myc protein is upregulated, miR-34a will inhibit
p53-dependent apoptosis [49]. c-myc is upregulated in 90% of
esophageal adenocarcinomas, and in esophageal cancer cells [50].
Hence, the possibility exists that curcumin circumvents the
negative effect of c-myc by not upregulating miR-34a.
Let-7a is a tumor suppressor miRNA and is down regulated in
many cancers. Curcumin treatment significantly increased let-7a
miRNA expression. A recent study demonstrated that let-7a
inhibits proliferation of human prostate cancer cells by targeting
E2F2 and CCND2. Both these proteins are cell-cycle regulators
Figure 7. Curcumin treatment inhibits oncomiR miRNA in
esophageal cancer cells. (A) real-time reverse transcription-PCR
analysis of total miRNA from TE-7 cells following 30 mM of curcumin
treatment for 24 h. Curcumin treatment significantly inhibit oncomiR
miRNA expression in TE-7 cells (*P,0.05). (B) Curcumin treatment
significantly up-regulated tumor suppressor let-7a miRNA expression in
TE-7 cells.
doi:10.1371/journal.pone.0030590.g007
Figure 8. Schematic diagram of the effect of curcumin on
Notch signaling in esophageal cancer. Our studies demonstrate
that curcumin inhibits the expression of Jagged-1 and the Notch-1
receptor. Curcumin also inhibits c-secretase complex proteins, thereby
inhibiting cleavage of the Notch receptor. As a result, the Notch
intracellular domain (NICD) is not released and therefore does not
translocate to the nucleus to activate the downstream target genes c-
myc and cyclin D1. This results in inhibition of cell proliferation and of
stem cell regeneration, while at the same time the induction of
apoptosis.
doi:10.1371/journal.pone.0030590.g008
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proliferation [51]. There is also an interesting link between
curcumin, microRNAs and Notch-1 regulation. Curcumin
upregulates the expression of miR-22 in human pancreatic cancer
cells especially [34]. Recent studies have also shown that treatment
of PanC-1 or Colo-357 cells with genistein (isoflavone) showed
decreased expression of the oncogenic miRNA such as miR-17,
miR-20a, miR-106a, and increased the expression of the tumor
suppressor miRNAs such as let-7, miR-16-1 [52]. More impor-
tantly, a recent study by Sarkar and colleagues demonstrated that
Notch-1 induced the expression of miR-21 while inhibiting the
expression of let-7a [53]. Our studies fit with these results in that
while curcumin inhibited Notch-1 expression, it also inhibited
expression of miR-21 while inducing let-7a.
In conclusion, these studies provide mechanistic evidence that
curcumin treatment inhibits cell growth in vitro. Curcumin seems
to have multiple molecular targets and its enhanced potency in
cancer in various cancer cell lines and xenograft tumors renders it
a strong candidate for therapeutic applications for esophageal
cancer as well as other cancers and inflammatory disease states.
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